121 related articles for article (PubMed ID: 7721232)
1. Effects of oxodipine and elgodipine on (+)-[3H]-isradipine binding to cardiac and vascular membranes: cardiovascular selectivity.
Rakotoarisoa L; Leprêtre N; Mironneau J; Galiano A; Mironneau C
Fundam Clin Pharmacol; 1994; 8(6):546-52. PubMed ID: 7721232
[TBL] [Abstract][Full Text] [Related]
2. Electrophysiological and radioligand binding studies of elgodipine and derivatives in portal vein myocytes.
Lepretre N; Arnaudeau S; Mironneau J; Rakotoarisoa L; Mironneau C; Galiano A
J Pharmacol Exp Ther; 1994 Dec; 271(3):1209-15. PubMed ID: 7996428
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of L-type Ca2+ channels in portal vein myocytes by the enantiomers of oxodipine.
Baron A; Rakotoarisoa L; Leprêtre N; Mironneau J
Eur J Pharmacol; 1994 Sep; 269(1):105-13. PubMed ID: 7828652
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of Ca2+ channel blockade by oxodipine and elgodipine in rat cardiomyocytes.
Galán L; Talavera K; Vassort G; Alvarez JL
Eur J Pharmacol; 1998 Sep; 357(1):93-105. PubMed ID: 9788778
[TBL] [Abstract][Full Text] [Related]
5. Effect of S-312, a new calcium channel blocker, on the 1,4-dihydropyridine binding sites in porcine basilar blood vessels and rat aortic smooth muscle cells.
Mihara S; Fujimoto M
Jpn J Pharmacol; 1991 Jul; 56(3):249-59. PubMed ID: 1832726
[TBL] [Abstract][Full Text] [Related]
6. Radioligand and functional estimates of the interaction of the 1,4-dihydropyridines, isradipine and lacidipine, with calcium channels in smooth muscle.
Salomone S; Godfraind T
Br J Pharmacol; 1993 May; 109(1):100-6. PubMed ID: 8495233
[TBL] [Abstract][Full Text] [Related]
7. (+)-[3H]-PN 200-110 binding to cell membranes and intact strips of portal vein smooth muscle: characterization and modulation by membrane potential and divalent cations.
Dacquet C; Loirand G; Rakotoarisoa L; Mironneau C; Mironneau J
Br J Pharmacol; 1989 May; 97(1):256-62. PubMed ID: 2524235
[TBL] [Abstract][Full Text] [Related]
8. Effect of dihydropyridines on calcium channels in isolated smooth muscle cells from rat vena cava.
Mironneau J; Yamamoto T; Sayet I; Arnaudeau S; Rakotoarisoa L; Mironneau C
Br J Pharmacol; 1992 Feb; 105(2):321-8. PubMed ID: 1373097
[TBL] [Abstract][Full Text] [Related]
9. Modulation of [3H]dihydropyridine binding by activation of protein kinase C in vascular smooth muscle.
Mironneau C; Rakotoarisoa L; Sayet I; Mironneau J
Eur J Pharmacol; 1991 Nov; 208(3):223-30. PubMed ID: 1663046
[TBL] [Abstract][Full Text] [Related]
10. Residual inhibition in density of [3H]isradipine binding sites in rat brain membrane pretreated with amlodipine.
Qu YL; Takamizawa C; Sugiyama K; Maruyama K; Hattori K; Watanabe K; Nagatomo T
Zhongguo Yao Li Xue Bao; 1995 Jul; 16(4):289-93. PubMed ID: 7668092
[TBL] [Abstract][Full Text] [Related]
11. Interactions of spironolactone with (+)-[3H]-isradipine and (-)-[3H]-desmethoxyverapamil binding sites in vascular smooth muscle.
Mironneau J; Sayet I; Rakotoarisoa L; Dacquet C; Mironneau C
Br J Pharmacol; 1990 Sep; 101(1):6-7. PubMed ID: 2149292
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic interaction between mibefradil and other calcium channel blockers.
Matthes J; Huber I; Haaf O; Antepohl W; Striessnig J; Herzig S
Naunyn Schmiedebergs Arch Pharmacol; 2000 Jun; 361(6):578-83. PubMed ID: 10882031
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of the potent and long-lasting antihypertensive action of the new calcium channel blocker pranidipine. Evidence for strong affinity to the calcium channels or membranes.
Miyakoda G; Nakayama N; Matsui K; Yabuuchi Y
Arzneimittelforschung; 1995 Apr; 45(4):471-5. PubMed ID: 7779144
[TBL] [Abstract][Full Text] [Related]
14. Interaction of pinaverium (a quaternary ammonium compound) with 1,4-dihydropyridine binding sites in rat ileum smooth muscle.
Feron O; Wibo M; Christen MO; Godfraind T
Br J Pharmacol; 1992 Feb; 105(2):480-4. PubMed ID: 1313732
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of Ca2+ channels in smooth muscle.
Mironneau J
Z Kardiol; 1991; 80 Suppl 7():43-6. PubMed ID: 1665262
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular effects of the new dihydropyridine derivative elgodipine.
Tamargo J; López-Sendón J; Delpón E; González-Morales M; de Miguel E
Arzneimittelforschung; 1991 Sep; 41(9):895-900. PubMed ID: 1796916
[TBL] [Abstract][Full Text] [Related]
17. A comparison between the binding and electrophysiological effects of dihydropyridines on cardiac membranes.
Hamilton SL; Yatani A; Brush K; Schwartz A; Brown AM
Mol Pharmacol; 1987 Mar; 31(3):221-31. PubMed ID: 2436031
[TBL] [Abstract][Full Text] [Related]
18. Calcium channel blocking properties of SM-6586 in rat heart and brain as assessed by radioligand binding assay.
Qu YL; Sugiyama K; Nagatomo T; Maniwa T; Miyagishi A
Jpn J Pharmacol; 1993 Oct; 63(2):165-9. PubMed ID: 8283826
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of 3H-nitrendipine binding in rat aortic and cerebral cortex membranes by the new dihydropyridine calcium antagonist benidipine hydrochloride.
Ishii A
Arzneimittelforschung; 1989 Dec; 39(12):1546-50. PubMed ID: 2624603
[TBL] [Abstract][Full Text] [Related]
20. Tissue response selectivity of calcium antagonists is not due to heterogeneity of [3H]-nitrendipine binding sites.
Bristow MR; Ginsburg R; Laser JA; McAuley BJ; Minobe W
Br J Pharmacol; 1984 Jun; 82(2):309-20. PubMed ID: 6329392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
